Amendment ID: S2499-19

Amendment 19

Transparency of Cost-Effectiveness Analysis

Mr. Crighton moves that the proposed new draft be amended in section 21, line 245, by inserting the following paragraph:-

Prior to any action that impacts enrollee access to treatments and services, the Commission shall (i) make public the retention or use of any third party providing cost-effectiveness analysis or research related to the proposed value of the eligible drug; (ii) make a comprehensive list of the information, cost-effectiveness analysis, reports or research provided by any third party related to the proposed value of the eligible drug used by the Commission, (iii) provide for a notice and public comment period by stakeholders and the public on the retention any third party and the cost-effectiveness analysis or research used by said third party related to the proposed value of the eligible drug used by the Commission.